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 CURRENTOPINION Epigenetics in rheumatoid arthritis
Kerstin Klein and Steffen Gay
Purpose of review
To give an overview of recently published articles addressing the role of epigenetic modifications in
rheumatoid arthritis (RA). Here we focused on DNA methylation and posttranslational histone modifications.
Recent findings
Recent studies attempted to link epigenetic modifications with genetic or environmental risk factors for RA.
There is evidence that histone deacetylases confer effects of environmental triggers such as smoking, diet or
therapy on expression levels of target genes. Additionally, disturbed methylation patterns and cell-type
specific histone methylation marks were identified as potential mediators of genetic risk in RA. Altered
methylome signatures were found in several cell types in RA, first of all RA synovial fibroblasts, and
contribute to the intrinsic fibroblast activation. The reversal of DNA hypomethylation by inhibiting the
polyamine recycling pathway was suggested as new epigenetic therapy in RA. Moreover, targeting
epigenetic reader proteins, such as bromodomain proteins, emerged as a new field in drug development
and the first studies underscored the potential of these drugs not only in malignant and inflammatory
conditions but also in autoimmune diseases.
Summary
Epigenetic factors represent a promising area to link genetics, regulation of gene expression and
environmental risk factors.
Keywords
bromodomain protein, DNA methylation, histone, rheumatoid arthritis
INTRODUCTION
Rheumatoid arthritis (RA) is an autoimmune dis-
ease, characterized by chronic inflammation of the
joints with severe pain and swelling, joint damage
and disability, which leads ultimately to joint
destruction and loss of function. RA can be divided
into two major subsets based on the presence or
absence of antibodies to citrullinated peptide anti-
gens (ACPA) [1]. The best know genetic risk factor
for ACPAþ RA is the presence of certain human
leukocyte antigen (HLA) class II alleles. Several
genome-wide association studies (GWAS) have
identified genetic variants across different popu-
lations that confer risk to RA. However, these vari-
ants can explain only less than 20% of susceptibility
in ACPAþ RA and even less in ACPA RA. The
contribution of environmental triggers including
smoking, the best known environmental risk factor
for RA, is essential to RA pathogenesis [2,3]. The
understanding of the interplay between immunity,
life style as well as genetic and environmental
factors is poor and is key to explaining the cause
of RA. Epigenetic factors represent a promising area
to link genetics and gene expression with disease
risk [3].
EPIGENETIC FACTORS AS REGULATORS
OF GENE EXPRESSION
The term ‘epigenetics’ was originally associated with
heritable changes in gene activity that occur with-
out alterations of the genetic code. Nowadays, the
term is more often used to describe chromatin-
related regulatory mechanisms that do not involve
changes in the nucleotide sequence, regardless of
whether such imprinting is strictly heritable [4].
Posttranslational histone modifications such as
acetylation, methylation or phosphorylation marks
among others are added to histone side chains or to
cytosine residues in the DNA (DNAmethylation) by
epigenetic ‘writer’ proteins (Fig. 1). These epigenetic
marks are recognized by ‘reader’ proteins that serve
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as platforms and docking sites for effector proteins
mediating fundamental processes such as trans-
cription, DNA replication and recombination,
DNA damage response and chromatin remodeling.
Epigenetic ‘eraser’ proteins are capable of removing
epigenetic marks. Understanding the intricate
spatial and temporal interplay between different
epigenetic modifications is one of the most
challenging aspects in chromatin biology and at
the beginning of exploration [4].
In addition to posttranslational histone modifi-
cations and DNA methylation, noncoding RNAs are
additional factors that influence gene expression
levels. Apart from microRNAs [5], which are small
noncoding RNAs acting as destabilizers and
repressors of translation, the functional role of
other noncoding RNAs in RA has not been inves-
tigated yet. Long noncoding RNAs with a length of
at least 200 nucleotides regulate gene expression
levels by affecting the stability of mRNA, altering
the translation efficiency, and functioning as pre-
cursors for mRNAs. Furthermore, long noncoding
RNAs are capable of controlling the epigenetic
state of particular genes by guiding chromatin-
modifying complexes and other nuclear proteins
to specific genomic loci to exert their effects [6].
Song et al. [7] have recently shown an altered
pattern of long noncoding RNAs in peripheral
blood mononuclear cells (PBMC) of RA patients
compared with healthy controls but their impact
on disease pathogenesis is at the beginning of
investigation.
DNA METHYLATION
Methylation of DNA is carried out by the activity
of DNA methyl transferases (DNMT), leading to the
formation of 5-methylcytosine (5-mC). Most
research so far has focused on the role of 5-mC in
CpG rich regions, called CpG islands. They are
enriched in promoters in the vicinity of transcrip-
tional start sites and their methylation blocks the
initiation of transcription and is associated with
long-term gene silencing including X-chromosome
inactivation [8].
An altered DNA methylome signature in syno-
vial fibroblasts derived from RA and osteoarthritis
patients, in PBMC from RA patients and healthy
controls, as well as reduced amounts of 5-mC in
synovial tissues of RA patients were described by
different research groups [9,10,11
&
]. Hypomethy-
lated genes clustered in key pathways related to cell
migration, including focal adhesion, cell adhesion,
transendothelial migration and extracellular matrix
interactions [11
&
]. Karouzakis et al. [12
&
] showed that
increased levels of the polyamine-modulated factor
1-binding protein 1 (PMFBP1) and the spermidine/
spermine N1-acetyltransferase (SSAT1) in rheuma-
toid arthritis synovial fibroblasts (RASF) enhanced
the catabolism and recycling of polyamines. The
authors suggested that the high consumption of
S-adenosyl methionine (SAM), the methyl donor
during DNA methylation via this pathway as an
important factor contributing to the global DNA
hypomethylation in RASF [12
&
]. In a follow-up study,
Neidhart et al. [13
&&
] recently suggested a new thera-
peutic concept for inhibiting the ongoing joint
destruction in RA based on the inhibition of the
polyamine recycling pathway by using diminazene
KEY POINTS
 Epigenetic modifications can serve as intermediaries of
genetic risk and environmental factors in RA.
 Inhibition of the polyamine recycling pathway reverses
the hypomethylation in rheumatoid arthritis synovial
fibroblasts (RASF) and reduces the invasiveness of RASF
in vivo.
 Targeting epigenetic reader proteins such as
bromodomain and extraterminal proteins might become
new therapies in autoimmune diseases.
Reader
Reader
Writer
Nucleosome
Posttranslational
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Effector
Eraser
FIGURE 1. Epigenetic writer, reader and eraser proteins.
Posttranslational histone modifications such as acetylation,
methylation or phosphorylation marks are added to histone
side chains by writer proteins and are recognized and get
bound by reader proteins. Epigenetic reader proteins serve
as a platform and docking site for effector proteins.
Posttranslational histone modifications are removed by eraser
proteins.
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aceturate, an inhibitor of the SSAT-1, alone, or in
combination with SAM/L-methionine. The authors
showed that SSAT-1 inhibition reduced the
adhesion abilities and expression levels of matrix
metalloproteinase (MMP) 1 in RASF as well as the
invasiveness of RASF that were coimplanted with
cartilage into the severe combined immuno-
deficiency mouse model [13
&&
]. This would be the
first therapy targeting RASF.
Besides global changes in DNA methylation,
promoters of specific genes were shown to be
hypomethylated or hypermethylated in RA in
different cell types [14,15,16
&
,17]. The methylation
of a single CpG site in the promoter of cytotoxic
T-lymphocyte-associated protein 4 (CTLA-4) in
regulatory T cells (Treg) of RA patients was shown
to result in impaired binding of the transcription
factor nuclear factor of activated T cells 2 (NFAT2)
leading to decreased expression levels of CTLA-4 in
RA patients compared with healthy controls. As a
consequence, Treg were unable to activate the
tryptophan-degrading enzyme indoleamine 2,3-di-
oxygenase and therefore failed to activate the
immune modulatory kynurenine pathway [16
&
].
These results implicate that small epigenetic
changes can impact the function of a whole cell
type in RA, in this case Treg.
HISTONE ACETYLATION
Histone acetylation and deacetylation are executed
by the activity of two opposing enzyme families:
histone acetylases (HAT) and histone deacetylases
(HDAC). HDAC exert the epigenetic control of
transcriptional activity by removing negatively
charged acetyl groups from lysine residues of
histones leading to the condensation of chromatin
and reducing the accessibility for transcription fac-
tors. The human genome contains 18 genes encod-
ing for HDAC that are classified into four groups
based on structural and functional similarities.
Whereas class I HDAC (HDAC 1, 2, 3, 8) are widely
expressed and present in nuclei, class II HDAC
(HDAC 4–7, 9) exhibit a more limited expression
pattern and are able to shuttle between the nucleus
and the cytoplasm. Sirtuins (SIRT 1–7) are members
of class III HDAC and require NADþ for their enzy-
matic activity. HDAC11 is the sole member of class
IV HDAC [18]. In addition to dietary factors that are
known to affect HDAC activity [19], treatment of RA
patients with antitumor necrosis factor (TNF) a
therapy was shown to increase the HAT/HDAC ratio
in nuclear extracts of PBMC, whereas rituximab
increased nuclear activity of both HAT and HDAC
[20]. Recently, direct effects of smoking on changes
in gene expression levels in joints were described
[21
&&
,22
&
] and SIRT6 was identified as one of the
mediators of smoke-induced changes in RASF.
Engler et al. [22
&
] showed that SIRT6 levels were
increased in synovial tissues of smokers and SIRT6
levels correlated with the disease duration in
smokers but not in nonsmokers. They showed that
the up-regulation of SIRT6 in RASF under exposure
to cigarette-smoke extract or TNFa functions as
counterregulatory mechanism attenuating the
production of MMP1 [22
&
]. These findings were in
line with a previous report revealing an anti-inflam-
matory and antidestructive role of SIRT6 in RASF
in vitro and in the collagen-induced arthritis (CIA)
mouse model in vivo [23
&&
]. On the contrary, SIRT1,
expression levels of which are increased in synovial
tissues and synovial cells of RA patients, was
shown to have proinflammatory properties and
contributes to the apoptosis-resistant phenotype
seen in RASF [24]. These reciprocal functions of
SIRT1 and SIRT6 in RASF underscore the importance
of performing functional studies on individual
members of HDAC families.
Different HDAC inhibitors (Table 1), which
mostly target several members of HDAC, were
described to have beneficial effects in vitro and
in vivo in RA [17,25–31]. However, many of the
observed effects of HDAC inhibitors were shown
to be chromatin-independent and nonepigenetic
(reviewed in [17]). Further studies [29–31]
(Table 1) have been published within the last
2 years using new and even more potent HDAC
inhibitors. Ahmed et al. [29] showed that Largazole
(LAR), a marine-derived class I HDAC inhibitor,
suppressed the TNFa-induced expression of intra-
cellular adhesion molecule-1 (ICAM-1) and vascular
adhesion molecule-1 (VCAM-1) in RASF, whereas
the TNFa-induced MMP2 activity was reduced.
Furthermore, the authors showed that LAR modu-
lated expression levels of HDAC1, HDAC5 and
HDAC6 and indicated a role of HDAC6 in the
LAR-induced changes of ICAM-1 and VCAM-1
expression levels. These results again point to the
need for understanding the exact role of different
HDAC enzymes in the RA pathogenesis in order to
develop highly effective HDAC inhibitors for the
treatment of RA [29].
EPIGENETIC MECHANISMS AS AN
INTERMEDIARY OF GENETIC RISK
Recent research efforts tried to integrate epigenetic
mechanisms into genetic susceptibility loci as causes
of the disease [32
&&
,33
&&
]. Liu et al. [32
&&
] performed a
genome-scale methylation and single nucleotide
polymorphism (SNP) analysis in leukocytes derived
from ACPAþ patients. The authors identified nine
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clusters of differentially methylated signatures in
the MHC region and one outside on the same
chromosome that likely mediate the genetic risk
for RA [32
&&
]. Furthermore, in a three-stage trans-
ethnic meta-analysis of GWAS data, an enrichment
of non-MHC risk loci was assessed in epigenetic
chromatin marks [33
&&
]. Histone 3 lysine 4 trime-
thylation (H3K4me3), a mark that highlights active
promoters and enhancers, was previously shown to
be the histonemark that ismost phenotypically cell-
type specific [34]. RA risk loci in biological candidate
genes overlapped with H3K4me3 peaks in immune-
related cells, especially in Treg [33
&&
].
OTHER POSTTRANSLATIONAL HISTONE
MODIFICATIONS
Only a few studies analyzed the role of other
posttranslational histone modifications than
acetylation in RA (reviewed in [17]). Recently,
the first study on histone phosphorylation in
arthritis was published. The authors identified an
overexpression of Aurora kinases A (AURKA) and B
(AURKB) in mononuclear cells derived from
proteoglycan-induced arthritis (PGIA) mice and
PBMC derived from treatment naive RA patients
compared with healthy controls by screening 84
known chromatin-modifying enzymes. Increased
AURKA and AURKB levels in B cells derived from
PGIA mice correlated with elevated levels of phos-
phorylated histone 3. Treatment with a pan-aurora
kinase inhibitor promoted B-cell apoptosis and
attenuated inflammatory reactions in arthritic
mice [35
&
].
TARGETING EPIGENETIC READER
PROTEINS
In recent years, much effort was put into the devel-
opment of small molecule inhibitors of the bromo-
domain and extraterminal (BET) family (BRD2,
BRD3, BRD4, BRDT) of bromodomain proteins.
BET proteins are readers of the e-N-acetylation of
lysine residues (Kac) on histone tails, a modification
that is associated with an open chromatin architec-
ture and transcriptional activation [36]. First clinical
trials using the BET inhibitors I-BET762 for the treat-
ment of nuclear protein in testis (NUT) midline
carcinomas, OTX015 for the treatment of hemato-
logical malignancies and CPI-0610 for the treatment
of lymphomas have started recently (reviewed in
[37]), underscoring the potential of this class of
inhibitors. However, BET inhibition as a point of
therapeutic intervention also became of interest in
autoimmune conditions because of the strong anti-
inflammatory properties of BET inhibitors [38,39]. A
first hint for an association of BET proteins with RA
came from a study by Mahdi et al. [40] in which
specific interactions between genotype, smoking
and autoimmunity to citrullinated a-enolase were
analyzed. Three SNPs in the BRD2 locus were found
to be associated with a subset of RA patients positive
for citrullinated a-enolase peptide 1 and cyclic
citrullinated peptides, independently of the HLA-
DRB1 shared epitope alleles [40]. In addition, a SNP
in the locus of another epigenetic reader protein,
namely BRD1 (BRPF2) was shown to be protective
in joint damage progression in stage I of a GWAS in
ACPAþ RA patients [41]. Recently, therapeutic
dosing of the BET inhibitor JQ1 was proven to be
RASF
Effector
proteins
Histone
acetylation
RASF Histone
acetylation
TNFα, IL1β
TLR ligands
TNFα, ILβ
TLR ligands
Ac Ac Ac
Ac Ac Ac
BRD2
BRD3
BRD4
Transcription
MMPs, cytokines, chemokines
MMPs, cytokines, chemokines
Rates of proliferation
Chemoattraction
I-BET 151
(a) (b)
FIGURE 2. Targeting epigenetic reader proteins with I-BET151. (a) Acetylated side chains of histones are recognized by the
epigenetic reader proteins BRD2, BRD3 and BRD4, leading to the recruitment of effector proteins and the activation of
transcription. (b) I-BET151 is a histone mimic that prevents BRD2, BRD3, and BRD4 from binding to acetylated histone side
chains, suppresses the transcription of matrix degrading enzymes, inflammatory cytokines and chemokines after stimulation
with TNFa, interleukin-1b or Toll-like receptor (TLR) ligands and reduces proliferation rates and the chemoattractive potential of
RASF. BET, bromodomain and extraterminal; RASF, rheumatoid arthritis synovial fibroblasts; TNF, tumor necrosis factor.
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efficacious in two mouse models of autoimmunity,
the models for CIA and for experimental auto-
immune encephalomyelitis (EAE); BET inhibition
suppressed the differentiation and activation of
Th17 cells [42
&&
]. Furthermore, we have shown that
the inhibitor I-BET151 suppressed the expression of
a broad range of inflammatory mediators and
matrix degrading enzymes in RASF in the presence
of cytokines or Toll-like receptor (TLR) ligands
(Fig. 2). Furthermore, I-BET151 reduced prolifer-
ation rates of RASF and chemotactic properties
towards PBMC (Klein et al., unpublished). However,
the individual roles of BET proteins in mediating
effects of different BET inhibitors in inflammatory
and autoimmune conditions has hardly been
investigated yet.
Besides targeting bromodomain proteins [37],
readers of other epigenetic marks including selected
members of methyl-lysine binding site readers were
predicted to have good drugability and first inhibi-
tors are in development [43].
CONCLUSION
The comprehension of the role of epigenetic factors
contributing to the pathogenesis of RA has increased
in recent years. A future challenge is to reveal the
interplay between different epigenetic modifi-
cations and to implement more functional studies
in order to understand underlying mechanisms of
epigenetic factors in different cell types contributing
to RA pathogenesis.
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